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Terminology and definitions 
 
Acquired resistance: Describes development of insusceptibility or a decrease in 
susceptibility resulting from genetic changes in a microorganism due to mutation or the 
acquisition of genetic material. 
 
Antibiotics: The term has traditionally referred to natural organic compounds synthesised by 
microorganisms that kill or inhibit growth of other microorganisms. Many antibacterial agents 
in clinical use are derived from natural products, but most are then chemically modified (i.e. 
semi-synthetic) to improve their properties. Some agents are totally synthetic (e.g. 
sulphonamides, quinolones). Therefore, the terms “antibacterial agent” or “antimicrobial 
agent” are preferred to “antibiotic” to include both natural and synthetic compounds. 
However, in the literature the term antibiotic is also often used for semi-synthetic and 
synthetic compounds.  
 
Antimicrobial agents: A general term for the drugs (antibiotics), chemicals, or other 
substances that either kill or stop the growth of microbes. The concept of antimicrobial agents 
applies to disinfectants, preservatives, sanitising agents, and biocidal products in general.  
 
Antimicrobial resistance: The characteristic of a strain of a microorganism that enables it to 
survive or avoid inhibition by a defined concentration of an antimicrobial agent. While the 
terminology regarding antimicrobial action and resistance is well-understood, that relating to 
biocidal resistance is still the subject of debate. A culture is considered resistant to a biocide 
when it is not inactivated by a common in-use concentration of a biocide, or by a biocide 
concentration that inactivates other strains of that organism. 
 
Antimicrobial susceptibility: Describes the degree to which a target microorganism is 
affected by an antimicrobial agent. There are no clear “cut-off” concentrations that are widely 
accepted to denote sensitivity or resistance of the various bacterial species to disinfecting 
agents. 
 
Antiseptic agent: A substance applied topically to living tissue that prevents or inhibits the 
growth of microorganisms. 
 
Biocide/Biocidal products: According to Directive 98/8/EC of the European Parliament and 
of the Council of 16 February 1998 concerning the placing of biocidal products on the market, 
biocidal products are defined as “Active substances and preparations containing one or more 
substances, put up in the form in which they are supplied to the user, intended to destroy, 
deter, render harmless, prevent the action of, or otherwise exert to controlling effect on any 
harmful organism by chemical or biological means”. The word “biocide” is in common use, 
and means a “biocidal product”. 
 
Biofilm: Microbial biofilms are populations of microorganisms that are concentrated at an 
interface (usually solid/liquid), and typically surrounded by an extracellular polymeric slime 
matrix. Flocs are suspended aggregates of microorganisms surrounded by an extracellular 
polymeric slime matrix that is formed in liquid suspension. 
 
Co-resistance: The process in which selection for resistance to one type of antimicrobial also 
selects for resistance to another antimicrobial agent due to linkage of the resistance genes on 




Cross-resistance: The process in which resistance to one antimicrobial agent confers 
resistance to another since the same mechanism of resistance applies to both drugs.  
 
Disinfectant: A substance that is used in the inanimate environment to destroy or eliminate 
specific species or groups of microorganisms. 
 
Intrinsic resistance: A natural property of an organism resulting in decreased susceptibility 
to a particular antimicrobial agent.  
 
Minimum Inhibitory Concentration (MIC): The lowest concentration of a given agent that 
inhibits growth of a microorganism under standard laboratory conditions.  
 
Normal flora: Indigenous microbial flora of human external, and some internal, surfaces like 
the skin, mouth, gastrointestinal tract, and upper respiratory tract.  
The normal flora contains numerous bacterial species, and numerous strains within each 
species. Although it may contain pathogens, the vast majority are commensals that contribute 
to general health as well as to resistance to colonization by pathogens. However, some low-
virulence bacteria of the normal flora may, under certain circumstances, become opportunistic 
pathogens.  
 
Selection: A process by which some bacterial species or strains of bacteria in a population are 
selected for by having a specific advantage over other microorganisms. Antibacterial 
substances may provide a more resistant sub-population with such an advantage, enabling 
them to increase their relative prevalence.  
 






Chlorhexidine and its salts are reported as being used in cosmetics as an active ingredient to 
give the desired effect or as a preservative in concentrations of up to 0.3 %.  Such products 
include mouthwashes, hair dying and bleaching formulations, shampoos, anti hair “aging” 
products and exfoliants, body lotions, eye creams, face cleansers, sun cream, after-sun lotions, 
eye makeup removers, and facial masks. Within the health sector, chlorhexidine is used in 
formulations for preoperative skin disinfection, in treatment of wounds and burns, for urinary 
bladder flushing, for catheter disinfection, and in ophthalmology and gynaecology. The 
commonly used concentrations in medical products range from 0.05 to 4 %. In cosmetic 
products, chlorhexidine is commonly used in combination with other agents with 
antimicrobial activity in order to improve the biocidal effect.   
 
The available information on chlorhexidine consumption is limited, but the total annual use of 
chlorhexidine in cosmetic products in Norway has been estimated to be 200 kg. In addition, 
chlorhexidine is applied in medical formulations, and in 2009 a total of  2 254 kg were used in 
such products (www.whocc.no).  
 
Bacterial resistance to chlorhexidine can be a natural property of the organism (intrinsic) or 
acquired by mutation and/or mobile genetic elements such as plasmids. The terms "intrinsic" 
and "acquired" resistance are related to resistance mechanisms, and a distinction should be 
made between these terms and the term "antimicrobial resistance" that is related to survival 
after exposure to the antimicrobial agent. Intrinsic resistance mechanisms towards 
chlorhexidine are particularly characteristic of Gram-negative bacteria, but also of bacterial 
spores, mycobacteria, and, under certain conditions, staphylococci also display such 
mechanisms. There are limited published data on acquired chlorhexidine resistance in 
bacteria, but from those available, acquired resistance towards chlorhexidine has been 
described from members of the Streptococcus spp., Staphylococcus spp,. and 
Enterobacteriaceae. This resistance may result from increased expression of chromosomally 
located efflux pumps, acquisition of plasmid-encoded efflux pumps, or changes in 
susceptibility by other presently unknown mechanisms.  
 
Literature on the development of resistance due to chlorhexidine in cosmetics is currently not 
available. However, it can be speculated that chlorhexidine in such products may add to the 
selection of microorganisms with increased tolerance to chlorhexidine. Although some reports 
on the correlation between chlorhexidine and antibiotic resistance are conflicting, some efflux 
pumps have been shown to mediate export of both chlorhexidine and other antimicrobial 
agents.  Cell wall changes that reduce their permeability may also play a role as a common 
resistance mechanism between chlorhexidine compounds and other antimicrobial agents, 
some of which are of clinical importance. Dissemination of plasmids carrying multi-resistance 
between staphylococci showing co-resistance to chlorhexidine and clinically important 
antibacterial agents has also been reported.  Thus, a contribution by chlorhexidine in cosmetic 
products to increased occurrence of resistance to clinically important antimicrobial agents 
cannot be excluded. However, resistance problems are  most probably of less importance for 





Klorheksidin og salt av klorheksidin vert brukte i kosmetikk enten som aktiv ingrediens som 
skal gi ynskt effekt eller som konserveringsmiddel i konsentrasjonar på opp til 0,3 %.  Slike 
kosmetiske produkt inkluderer munnskyljevatn, midlar for farging eller bleiking av hår, 
sjampoar, midlar mot ”håraldring”, hudskrubbepodukt, hudlotionar, kosmetiske augekremar, 
anletsrensarar, solkremar, ettersolingskremar, augesminkefjernarar og ansiktsmasker. Innan 
helsesektoren vert klorheksidin nytta i legemidlar for preoperativ huddesinfeksjon, ved 
handsaming av mekaniske sår og brannsår,  ved urinblæreskylling og i kateterdesinfeksjon. 
Dessutan er klorheksidin brukt innan oftalmologi og gynekologi. Vanlege konsentrasjonar i 
medisinske produkt er frå 0,05 to 4 %. I kosmetiske produkt vert klorheksidin ofte nytta 
saman med andre antimikrobielle stoff for å gi auka antimikrobiell effekt.    
 
Tilgjengeleg informasjon om bruk av klorheksidin er sparsam, men den totale årlege bruken i 
kosmetiske produkt i Noreg er estimert til 200 kg. I tillegg vert klorheksidin brukt i 
medisinske preparat, og i 2009 var den totale bruken i slike preparat på 2254 kg 
(www.whocc.no). 
 
Reistens mot klorheksidin hos bakteriar kan skuldast ein naturleg eigenskap hos organismen 
(ibuande resistens), etter den kan vera tileigna gjennom mutasjonar og/eller mobile genetiske 
element som plasmidar. Omgrepa ”ibuande” og "tileigna" resistens er knytt til mekanismar for 
resistens, og må skiljast frå omgrepet "antimikrobiell resistens" som er knytt til overleving 
etter eksponering for eit antimikrobielt stoff. Det å ha ibuande resistensmekanismar mot 
klorheksidin er særleg karakteristisk for Gram-negative bakteriar, men dette gjeld og for 
bakteriesporar, mykobakteriar og i nokre tilfelle også for stafylokokkar. Mengda publiserte 
data på tileigna klorheksidinresistens hos bakteriar er lita. Frå dei publikasjonane som er 
tigjengelege, vert tileigna reistens mot klorheksidin påvist hos medlemar av Streptococcus 
spp., Staphylococcus spp. og Enterobacteriaceae. Denne resistensen kan ha sitt opphav i auka 
genetisk uttrykk av kromosomalt bundne efflukspumper, tileigning av plasmidkoda 
efflukspumper eller som fylje av andre og så langt ikkje kjende mekanismar.   
 
Så langt er det ikkje tilgjengeleg littaratur om utvikling av resistens som fylje av 
klorheksidinbruk i kosmetiske produkt. Det er likevel mogeleg at klorheksidin i slike produkt 
kan vera medverkande til seleksjonen av mikroorganismar som har auka toleranse mot 
klorheksidin. Sjølv om det ser ut til å vera motstridande informasjon i den vitskapelege 
litteraturen om samvariasjonen mellom resistens mot klorheksidin og antibiotika, er nokre 
efflukspumper viste å stå for transport av både klorheksidin og andre antimikrobielle stoff ved 
ein og same pumpemekanisme. Endringar i celleveggen som fører til  redusert permeabilitet 
kan også spele ei rolle som ein sams resistensmekanisme for klorheksidin og andre 
antimikrobielle stoff som er klinisk viktige. Spreiing av multiresistensplasmid mellom 
stafylokokkar som viser ko-resistens mot klorheksidin og klinisk viktige antibakterielle stoff 
er også rapportert.  Ein kan derfor ikkje sjå bort frå at klorheksidin i kosmetiske produkt kan 
medverka til auka førekomst av resistens mot klinisk viktige antimikrobielle stoff. Det er 
likevel høgst samsynleg at resistensproblema for klorheksidin er mindre enn det ein ser for 




In 2009, the Norwegian Scientific Committee for Food Safety (VKM), Panel on Biological 
Hazards, received a request from the Norwegian Food Safety Authority to develop a risk 
assessment regarding development of resistance in microorganisms resulting from the use of 
chlorhexidine in cosmetic products. In response, an ad hoc Working Group of experts was 
appointed with the mandate to draft an assessment regarding this issue. 
 
2 Definition of cosmetic products  
According to the EU Cosmetics Directive (76/768/EEC), “a cosmetic product shall mean any 
substance or preparation intended to be placed in contact with the various external parts of the 
human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth  
and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning 
them, perfuming them, changing their appearance and/or correcting body odours and/or 
protecting them or keeping them in good condition.”  Furthermore, Norwegian regulations 
define cosmetic products as products that come into contact with the human body surface (skin, 
hair, nails, lips, and external genitals), teeth or mucous membranes of the oral cavity 
(Kosmetikklova, 2005).   
 
3 Terms of reference 
The Norwegian Food Safety Authority commissioned the Norwegian Scientific Committee 
for Food Safety to undertake a risk assessment on the application of chlorhexidine in 
cosmetics with special emphasis on the following topics1: 
 
1- Could the use of chlorhexidine in cosmetic products facilitate the development of 
resistance or reduced susceptibility (tolerance) towards chlorhexidine in 
microorganisms?  
2- Could the efficacy of clinically important antimicrobials be reduced by resistance 
development due to use of chlorhexidine in cosmetic products? If so, which classes of 
agents might be affected? 
3- Could use of chlorhexidine in cosmetic products alter the microflora of the skin or the 
oral cavity, or influence the virulence of these microorganisms?  
 
 
4 Hazard identification 
Hazard identification is implicit in the title of this risk assessment and in the terms of 
reference. 
 
                                                          
1 Oppdrag 
Mattilsynet ba VKM om en risikovurdering i forhold til bruk av klorheksidin i kosmetiske 
produkter. Følgende spørsmål ble spesielt ønsket besvart:   
 
1- Kan bruk av klorhexidin i kosmetiske produkter føre til resistens/nedsatt klorhexidin 
følsomhet hos mikroorganismer?   
2- Kan man få redusert effekt av klinisk viktige antimikrobiell midler som følge av mulig 
resistensutvikling ved bruk av klorhexidin i kosmetiske produkter?  I tilfelle hvilke 
klasser av antimikrobielle midler kan bli berørt?   
3- Kan bruk av klorhexidin i kosmetiske produkter gi endringer i hudens og munnhulens 
mikrobiota og dens virulensegenskaper?  
09-106-final 
 9




5.1.1 Chemical structure and properties 
 
Chlorhexidine is a bisbiguanide compound with antimicrobial activity against bacteria, 
viruses, and fungi (O'Neil 2006). The structural formula is provided in Figure 1. 
Chlorhexidine has been given the IUPAC name N,N,'-hexane-1,6-diylbis[N-(4-chlorophenyl) 
(imidodicarbonimidic diamide)], has a molecular formula of C22H30Cl2N10, and a molecular 
weight of 505.4 g/mol. 
 




Chlorhexidine is a white to pale yellow, odourless powder. It is only slightly soluble in water 
and most organic solvents. Since chlorhexidine itself is practically insoluble in water, the 
commonly used form is a salt of glucuronic acid, chlorhexidine gluconate.  Chlorhexidine 
gluconate is readily soluble in water and alcohol. Concentrated chlorhexidine gluconate is a 
colourless to pale yellow solution that is odourless and has a strong bitter taste. In aqueous 
solutions, chlorhexidine salts display maximum biological activity and chemical stability 
within a pH range of 5-8. 
 
Chlorhexidine gluconate was first synthesised in England by ICI Pharmaceuticals in the 1950s 
(DAVIES et al., 1954). It was reported to have a high antimicrobial activity, an affinity to 
skin and mucous membranes, and relatively low toxicity to human cells. Thus, it soon became 
popular as a topical antimicrobial agent (Paulson 2003). 
 
The antimicrobial activity of chlorhexidine gluconate is pH dependent, being optimal in the 
range 5.5 to 7.0 (Paulson 2003). This span corresponds with the pH normally found on human 
tissue where chlorhexidine gluconate may be commonly applied. 
 
5.1.2 Stability 
Diluted aqueous solutions of chlorhexidine in concentrations under 1 % are quite heat stable 
and may be sterilized by autoclaving at 123°C for 15 minutes. Autoclaving of solutions 
greater than 1.0 % can result in the formation of insoluble residues and is therefore unsuitable. 
According to producers of commercially available chlorhexidine, aqueous solutions may be 
stored at room temperature for at least one year, provided that the packaging is adequate 
(www.sigmaaldrich.com). Prolonged exposure to high temperature or light should be avoided 
as this affects the stability of chlorhexidine solutions. Aqueous solutions of chlorhexidine are 
most stable within the pH range of 5 to 8. Above pH 8.0, chlorhexidine base is precipitated 
and in more acidic conditions a gradual degradation of, and reduction in, the antibacterial 




Several authors report on the microbial degradation of chlorhexidine. Ogase et al. ( 1992) 
examined the degradation of chlorhexidine by two strains of Achromobacter xylosoxidans 
originally isolated from the reservoir in a hand-washing machine. These two strains were 
shown to be resistant to chlorhexidine, with MIC (Minimum inhibitory concentrations) values 
of 1000 µg/ml. The authors found pyrogallol, phenol, and p-chlorophenol to be important 
degradation products. Several intermediate compounds were predicted to be part of the 
metabolic degradation of chlorhexidine by microorganisms, including p-chloroaniline and 
phenol.  The experiments of Ogase et al. ( 1992) demonstrated the ability of microorganisms 
to degrade chlorhexidine. Indeed, Tanaka et al. ( 2005) found that an unidentified strain of 
Pseudomonas isolated from activated sludge degraded chlorhexidine to p-chloroaniline, as 
well as to two metabolites designated CHDI-B and CHDI-C. These two metabolites showed a 
tenfold reduction in the antibacterial activity towards several test strains, including Bacillus 
cereus, Escherichia coli, Staphylococcus aureus, Proteus vulgaris, and Serratia marcescens.     
 
5.1.3 Mode of action 
Most studies on the mode of action of chlorhexidine have been on bacteria. The positive 
charge of chlorhexidine attracts negatively charged proteins on the bacterial surfaces, 
resulting in physical disruption of the membranes, dissipation of the proton motive forces, and 
inhibition of membrane-associated enzymes. It is assumed that interactions with bacteria 
occur via cationic binding to phosphate groups of cell wall teichoic acid in Gram-positive 
bacteria (Albert 1942) and to phosphate groups in the cell walls and membranes of Gram-
negative bacteria (Heptinstall et al., 1970). 
 
At bacteriostatic concentrations, chlorhexidine inhibits membrane enzymes and disrupts the 
interactions between lipids and proteins in the membranes, leading to permeabilization and 
leakage of cellular components. At higher concentrations, cytoplasmic proteins coagulate, 
presumably through denaturation, and the cells die.  It is believed that the mode of action on 
fungi and protozoa is similar to that with bacteria, both through disruption of the cell 
membranes resulting in leakage of cellular components and penetration of the membranes 
leading to coagulation of cytoplasmic proteins. Chlorhexidine interacts with the envelope of 
enveloped viruses resulting in release of the viral capsid at high concentration. At lower 
concentrations, chlorhexidine may interact with envelope proteins or tail structures, resulting 
in inhibition of transduction (Denton 1991; Lambert 2004; Maillard 2004). 
 
5.1.4 Antimicrobial activity 
Chlorhexidine has a broad antimicrobial activity against bacteria, fungi, enveloped viruses, 
and protozoa (Denton 2009; Maillard 2004). 
 
Bacterial growth is inhibited at concentrations between 0.5 and 10 mg/L, and bactericidal 
activity is found at concentrations over 5 mg/L, depending on species and strain.  
Chlorhexidine is not lethal to bacterial spores or acid-fast bacteria. Fungi are more resistant to 
chlorhexidine than bacteria, with MIC of 10-200 mg/L and Minimum bactericidal 
concentration (MBC) of 20 (yeast) to over 200 mg/L (moulds). Chlorhexidine is lethal to 
protozoa at concentrations over 50-150 mg/L depending on species (see 5.3.1). The 
susceptibilities of viruses are highly variable and reported virucidal concentrations are 






5.2 Susceptibility testing 
The wide range of areas of application and target organisms makes it difficult to establish 
relevant and standardised tests for microbial susceptibility. For chlorhexidine compounds, 
both the ability to inhibit growth and to kill microorganisms may be of importance, depending 
on the area of use. The test conditions have a considerable influence on results and means that 
comparisons between investigations and extrapolation from laboratory to practical conditions 
are difficult. Due to the synergistic and antagonistic effects between different ingredients in 
cosmetics and chlorhexidine, the concentrations needed to inhibit growth and kill 
microorganisms may be higher or lower than reported in the literature. Chlorhexidine 
produces insoluble products with chloride, sulphate, phosphate, and citrate. The efficacy is 
reduced in the presence of organic materials such as serum, blood, and pus. Soaps and other 
anionic compounds also neutralize its activity (Moore & Payne 2004). Non-ionic surfactants 
may have synergistic and antagonistic effects with chlorhexidine depending on compound and 
concentration ratio (Schmolka 1973). A combination of several biocides/preservatives in the 
same cosmetic product is often used to increase the total antimicrobial activity, to extend the 
spectrum of activity, or to ensure antimicrobial action in both the water and oil phase. The 
effects of chlorhexidine can be enhanced by other biocides such as alcohols and QACs 
(McDonnell 2007). A combination of preservatives active in the oil phase (such as parabens) 
and the water phase (chlorhexidine) may be used in cosmetic emulsions (Hiom 2004).  
 
In conclusion, antimicrobial activity in cosmetic products containing several ingredients may 
be lower or higher than the antibacterial activity in laboratory model tests. Susceptibility tests 
in the laboratory can therefore be used to compare strains/species or in mechanistic studies 
(for example to test the effects of mutations), but are not necessarily useful for predicting 
survival in conditions of practical use. 
 
In vitro tests 
In tests for general inhibitory activity, microorganisms are exposed to chlorhexidine 
compounds in nutrient suspension or nutrient agar, and growth is determined after incubation 
for a specific time. The main advantages of the MIC method are that it is easy to perform and 
many strains or chlorhexidine compounds can be tested in the same experiment. There are no 
standard methods for determining the MIC of chlorhexidine compounds, and therefore 
various approaches have been described in the literature.  
 
In biocidal tests, microorganisms in suspension or on a surface are exposed to chlorhexidine 
compounds for a specific period of time, followed by neutralisation and determination of the 
number of viable microbes. For determining biocidal efficacy for usage in hand-washing or 
mouthwash preparations, the efficacy of products and/active components can be tested using 
European standardised tests for bactericidal, sporicidal, virucidal, and fungicidal activity  
(CEN 1997a; CEN 1997b; CEN 1997c; CEN 1997d; CEN 1998; CEN 2002a; CEN 2002b; 
CEN 2005). These test methods may be used for measuring strain susceptibility. 
 
In the tables presented by Denton (1991) there is generally little correlation between the 
tolerance level for chlorhexidine in the MIC test and the biocidal test. In another study, 
Pseudomonas aeruginosa strains with raised MIC to chlorhexidine were no less sensitive than 
the parent strain to chlorhexidine and benzalkonium chloride in bactericidal investigations 
(Thomas 2005). It is therefore difficult to draw conclusions about resistance to the biocidal 
effect of chlorhexidine based on results of MIC tests. 
 
Testing susceptibility under conditions of practical use 
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Standardised tests have been developed to test the efficacy of preservatives in cosmetic 
products  (British Pharmacopoeia Comission 2000; United States Pharmacopeia 2002). These 
methods could potentially be adapted to test susceptibility of microorganisms under 
conditions of practical use.  The challenge tests are based on inoculation of the 
pharmaceutical/cosmetic product with bacteria, followed by incubation and sampling for 
survivors during the storage period (Russell 2003).  
 
For assessing efficacy of hygienic hand-wash, a European standard in vivo test (EN1499) has 
been developed. The method is based on contamination of hands with a test strain, treating 
with the preparation and measuring the number of viable test organisms before and after 
treatment. The method can potentially be used to measure susceptibility of microorganisms to 
chlorhexidine. Standardised tests for measuring the resistance of microorganisms in 
conditions relevant to mouthwash are not available, and mouthwash preparations are often 
tested using in vitro test methods. Since the resistance of microorganisms is dependent on a 
range of environmental factors, results from these experiments are not readily extrapolated to 
practical conditions. 
 
5.3 Resistance mechanisms 
The terms "intrinsic" and "acquired" resistance are related to resistance mechanisms and 
should be distinguished from the term "antimicrobial resistance" that is related to survival 
after exposure to the antimicrobial agent. Bacterial resistance to chlorhexidine can be a 
natural property of the organism (intrinsic) or acquired by mutation and/or mobile genetic 
elements such as plasmids or transposons.  
 
5.3.1 Intrinsic resistance 
Intrinsic resistance to chlorhexidine is generally low level resistance/tolerance (see section 
5.1.4 and below for inhibiting concentrations of chlorhexidine) and thus for most organisms, 
with the exception of some viruses and A. xylosoxidans, well below the commonly used 
concentrations in both cosmetic (≤ 3 g/L) and medical products (≥ 0.5 g/L). 
 
There is an overall tendency for Gram-negative bacteria to be more resistant than Gram-
positive bacteria to chlorhexidine. Thus, intrinsic resistance to chlorhexidine is particularly 
demonstrated by Gram-negative bacteria (especially P. aeruginosa, Proteus spp., and 
Burkholderia cepacia), but also by bacterial spores, mycobacteria, and, under certain 
conditions, staphylococci. Spore coats and cortexes are responsible for the high tolerance of 
bacterial spores to chlorhexidine, while impermeability, due to outer membrane composition 
and decreased porin expression, contributes to the intrinsic resistance of vegetative cells 
(McDonnell & Russell 1999; Russel & Day 1993). In mycobacteria, the waxy cell walls and, 
specifically, the cell wall component arabinogalactan prevent adequate chlorhexidine entry 
(Broadley et al., 1995; McDonnell & Russell 1999). In P. aeruginosa, the outer membrane is 
responsible for its high tolerance, due to the high cation content that aids in the formation of 
strong lipopolysaccharide (LPS)-LPS links, and the presence of small-sized porins that do not 
permit general diffusion (Broadley et al., 1995; Brown 1975; McDonnell & Russell 1999). A 
less acidic outer membrane LPS, partly due to the high content of phosphate-linked arabinose 
in the LPS limiting its cation-binding capacity, probably contributes to the high intrinsic 
resistance to chlorhexidine of B. cepacia and some Proteus strains (Cox & Wilkinson 1991; 
McDonnell & Russell 1999). In S. aureus, the mucoidal slime layer seems to protect these 
Gram-positive cells against chlorhexidine (Kolawole 1984; McDonnell & Russell 1999). 
Certain Gram-negative bacteria produce vesicles by extrusion of their outer cell membranes 
that attach to bacteria and oral surfaces. Vesicles released by Porphyromonas gingivalis 
09-106-final 
 13 
probably promote tolerance to chlorhexidine by binding of chlorhexidine by the vesicle LPS. 
Vesicles released by P. gingivalis have been demonstrated to protect both P. gingivalis and 
other selected oral bacterial species against chlorhexidine concentrations that are 3 times that 
of their normal MIC (Grenier et al., 1995). 
 
Growth rate and growth-limiting nutrients affect the physiological states of cells and the 
presence of biocides, such as chlorhexidine, is likely to modify the degree of thickness and 
cross-linking of peptidoglycan. These factors might explain the modified response to biocides 
in Gram-positive bacteria such as Bacillus megaterium (Gilbert & Brown 1980; McDonnell & 
Russell 1999). 
 
Formation of biofilms prolongs survival of S. marcescens (Marrie & Costerton 1981), B. 
cepacia (Hugo et al., 1986), Enterococcus faecalis (Abdullah et al., 2005), and methicillin-
resistant S. aureus  (MRSA) (Oie et al., 1996) on exposure to chlorhexidine. Haemophilus 
influenzae, P. aeruginosa, MRSA, and Streptococcus mutans exposed to chlorhexidine 
showed a markedly increased percentage survival when growing in biofilms compared with 
planktonic cells (Izano et al., 2009; Kreth et al., 2008; Smith & Hunter 2008).  
 
In addition to outer membrane impermeability, intrinsic resistance can be associated with the 
activity of basal levels of efflux by pumps actively removing chlorhexidine from the 
membrane core. Efflux pumps contributing to intrinsic resistance of chlorhexidine include 
MepA in S. aureus (chlorhexidine MIC 0.04-1.25 mg/L) (Huet et al., 2008; Kaatz et al., 
2005), MexCD-OprJ pump in P. aeruginosa (chlorhexidine MIC 10 mg/L) (Fraud et al., 
2008), AcrAB-TolC in E. coli (Levy 2002), CepA in Klebsiella pneumoniae (chlorhexidine 
MIC 16-32 mg/L) (Fang et al., 2002), and to a lesser extent SdeXY in S. marcescens 
(chlorhexidine MIC 2.5 mg/L in E. coli) (Chen et al., 2003). Chromosomal efflux pumps can 
be induced, so that an apparently susceptible strain can overproduce a pump to become 
tolerant. It has been claimed that the activity of bisbiguanides, such as chlorhexidine, is 
unaffected by hyperexpression of efflux presumably because they do not become solubilised 
within the membrane core (Gilbert & Moore 2005). However, chlorhexidine can induce the 
MexCD-OprJ pump (chlorhexidine MIC >50 mg/L after serial passage in increasing 
concentrations of chlorhexidine) and hyperexpression of mexCD-oprJ in a mutant strain also 
enhanced chlorhexidine tolerance (chlorhexidine MIC 10 mg/L increased to 20 mg/L) (Fraud 
et al., 2008). It has recently been shown by global transcriptomic analyses of P. Aeruginosa, 
that chlorhexidine at sub-MIC concentrations (8 µM (4 mg/L)) up-regulated mexC and mexD, 
14 and 6 times respectively, after 10 minutes exposure time (Nde et al., 2009). The clinical 
consequence is, however, uncertain. 
 
Rather than preventing the drug from reaching its target, a cell can also inactivate the drug to 
become resistant. A chlorhexidine-degrading enzyme has been discovered in A. xylosoxidans 
(MIC chlorhexidine >125-500 mg/L) (Nagai & Ogase 1990; Ogase et al., 1992). 
 
The intrinsic resistance of non-enveloped viruses towards chlorhexidine is probably due to a 
reversible adsorption to the viral capsid. This adsorption does not lead to penetration inside 
the phage particles, but may result in inhibition in the transduction ability of the virus 
(Maillard & Beggs 2009). 
 
Studies on chlorhexidine resistance in fungi have mainly been conducted on the yeast 
Saccharomyces cerevisiae. The glucan composition of the cell wall may play a role in 
limiting entry of chlorhexidine into S. cerevisiae. Furthermore, uptake of chlorhexidine is 
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reduced in older cultures in which S. cerevisiae cells show increased cell wall thickness and 
reduced porosity (Hiom et al., 1995; Hiom et al., 1996). The yeast Candida albicans is less 
sensitive to chlorhexidine than S. cerevisiae due to lower uptake (Hiom et al., 1995).  Also C. 
albicans biofilms produce multidrug-tolerant subpopulations of persister cells that display 
resistance to chlorhexidine (growth in 100 mg/L chlorhexidine) that is not influenced by 
efflux transporters. Such persister formation is not dependent on formation of a complex 
biofilm structure, but rather on the ability to attach to a surface (Lafleur et al., 2006). For 
moulds that are generally more tolerant to chlorhexidine than yeasts, no studies are available 
that indicate the mechanism involved in their high intrinsic resistance. However, McDonnell 
and Russell ( 1999) speculate that cell wall composition is involved. 
 
For protozoa, the cyst forms are invariably the most tolerant to chemical disinfectants such as 
chlorhexidine (Khunkitti et al., 1998b; McDonnel & Russel 1999). The cellulose cyst wall 
appear to act as a barrier for uptake of chlorhexidine in Acanthamoeba castellanii thereby 
contributing to its high intrinsic resistance (Khunkitti et al., 1998a). The effect of biofilm 
formation on chlorhexidine tolerance by Acanthamoebae (Gray et al., 1995) has not been 
explored. 
 
5.3.2 Acquired resistance 
The resulting tolerance level due to the presence of acquired resistance mechanisms, including 
acquisition of the qacA gene described below, is far less than the commonly used 
chlorhexidine concentrations of up to 3 g/L in cosmetic products and between 0.5 and 40 g/L 
in products for medical use.  
 
Increased chlorhexidine efflux can be achieved by over-expression of chromosomal multidrug 
efflux protein MepA in S. aureus due to mutations resulting in premature termination or 
amino acid substitutions in the regulatory protein MepR or substitution in MepA 
(chlorhexidine MIC 0.04-1.25 mg/L increased 2-32 fold in mutants) (Huet et al., 2008; Kaatz 
et al., 2005). Mutational up-regulation of multidrug efflux pump SdeAB in S. marcescens also 
resulted in increased tolerance to chlorhexidine  (chlorhexidine MIC 25 mg/L increased to 
100 mg/L in mutant) (Maseda H et al., 2009). 
 
Acquisition of plasmid-encoded efflux pumps results in increased tolerance to chlorhexidine 
in staphylococci. QacA plasmid-encoded efflux pumps providing tolerance to chlorhexidine 
(MIC 2-4 mg/L) are common in clinical strains of S. aureus and other staphylococci 
(Leelaporn et al., 1994; Littlejohn et al., 1992; Paulsen et al., 1996; Poole 2002). The clinical 
significance of qacA mediated chlorhexidine tolerance has not been determined  (Milstone et 
al., 2008). Furthermore, no studies have been published testing how much QacA actually 
contributes to the raised chlorhexidine MIC levels in staphylococci. Studies comparing MIC 
for chlorhexidine in cells expressing QacA wild-type with cells expressing QacA mutants/no 
QacA have only been conducted in E. coli (Hassan et al., 2006; Hassan et al., 2008; Wu et al., 
2008). An unnamed antiseptic resistance protein, differing from QacA in size and providing 
tolerance to chlorhexidine (chlorhexidine MIC 6.25 mg/L), was found encoded on a 
transferable 50-kb plasmid in MRSA (Yamamoto et al., 1988).  
 
Finally, changes in susceptibility may include other currently unknown mechanisms. DNA 
from Streptococcus sanguis strains that had developed stable tolerance to chlorhexidine 
(chlorhexidine MIC 64-128 mg/L) was used to transform susceptible, competent S. sanguis to 
increased chlorhexidine tolerance (chlorhexidine MIC 64 mg/L) (Westergren & Emilson 
1980) proving that this tolerance was an inheritable trait. In Pseudomonas stutzeri, stable 
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tolerance to chlorhexidine (chlorhexidine MIC 50-100 mg/L) was probably developed by a 
mutation that resulted in nonspecific alteration of the cell envelope (Tattawasart et al., 1999), 
and stable adaptive tolerance to chlorhexidine was readily achieved in both Salmonella 
enterica serovar Virchow and E. coli O157 (Braoudaki & Hilton 2004), probably due to outer 
membrane modifications. In S. mutans, Clp serine protease, involved in the general stress 
response, assists S. mutans in resistance against chlorhexidine through adaptation (Deng et al., 
2007). 
 
To date, limited data have been published on acquired chlorhexidine resistance in bacteria. 
Most studies exploring substrate specificities of novel resistance mechanisms usually test 
resistance to quaternary ammonium compounds, rather than chlorhexidine, if a biocide is 
included in the test panel.  
 
5.4 Resistance among microbes in the normal flora of humans and in the 
environment  
 
The microflora of the skin 
The skin is generally an unfavourable place for microbial growth. It is subject to periodic 
drying and the pH ranges from 3 to 5, which is non-optimal for most bacterial species. 
However, certain species are able to establish themselves under such conditions, and these 
constitute the normal flora of the skin. The skin may be considered as a single organ, but its 
flora varies at different locations of skin surfaces. Bacterial populations in warm humid 
places, like the axillae, umbilicus, and interdigital spaces, are rich and numerous, in contrast 
with the microflora on dryer parts of the skin. Hair follicles, sebaceous glands, and sweat 
glands provide attractive habitats for microorganisms, where a variety of bacteria and fungi 
reside (Høiby 1993; Linton 1982; Madigan et al., 1997; Tortora et al., 1989; Tortora et al., 
1998). Many factors may influence the composition of microflora of an individual’s skin, 
including temperature, humidity, age, sex, race, and occupation (Roth & James 1988). 
 
The skin flora consists primarily of Gram-positive bacteria. Cultivation-based studies have 
shown that these include Staphylococcus spp., Micrococcus spp., Corynebacterium spp., 
Streptococcus spp., Propionibacterium spp., and yeasts belonging to the genus Pityrosporum 
(Cogen et al., 2008; Gao et al., 2007; Høiby 1993; Madigan et al., 1997; Tortora et al., 1989). 
However, little is known about the presence of non-cultivable or rare species in the 
microbiota of the skin, and a more complex microflora may be present (Gao et al., 2007). 
With the exception of Acinetobacter spp., Gram-negative bacteria are almost always minor 
constituents of the normal skin flora, (Cogen et al., 2008; Gao et al., 2007; Madigan et al., 
1997; Martro et al., 2003). 
 
The staphylococcal group can be divided into two subdivisions: coagulase-positive and 
coagulase-negative. Coagulase-positive staphylococci are regarded as the most virulent, and 
are more often associated with disease than coagulase-negative staphylococci. S. aureus is the 
most common coagulase-positive Staphylococcus species in man. S. aureus can sometimes be 
found on the skin of individuals who are nasal carriers, as the skin can be contaminated with 
bacteria from the mucosal linings of the nose. Several species of coagulase-negative 
staphylococci can be found on human skin, Staphylococcus epidermidis being the most 
common (Cogen et al., 2008). S. epidermidis and other coagulase-negative staphylococci are 
increasingly recognized as cause of nosocomial infections, and also play important roles in 
implant-related infections. S. aureus is of special concern since this is a leading human 
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pathogen. There has been a dramatic increase in S. aureus strains that are resistant to 
antimicrobial agents, including MRSA. MRSA are resistant to all beta-lactam antibiotics and 
are considered a major threat in human medicine. 
 
Staphylococci harbouring qac genes can be resistant to other antimicrobial agents (described 
under section 5.5). Several studies have shown the occurrence of qac genes in MRSA isolates 
(Gillespie et al., 1986; Mayer et al., 2001; Noguchi et al., 1999; Noguchi et al., 2005). An 
early investigation showed that among MRSA strains isolated in Japan in 1992, 10.2 % 
contained the qacA/B gene (Noguchi et al., 1999). Another study reported that among MRSA 
strains from Europe isolated during the period 1997 to 1999, 63 % contained the qacA/B gene 
(Mayer et al., 2001). Numerous successful MRSA clones have been described and 
characterized, and many have a worldwide distribution (Deurenberg et al., 2007). The 
presence of qac genes among MRSA clones is currently unknown. Selection of qac 
containing staphylococci may therefore contribute to increased occurrence of strains resistant 
to different antimicrobial agents. Although QacA may pump chlorhexidine, resulting in 
increased tolerance, the practical consequence is unknown. As the conferred resistance level 
is much lower than the concentrations used in cosmetics, it may be of negligible importance 
(Milstone et al., 2008). Thus, whether the presence of the qacA gene will be an advantage for 
staphylococci during exposure to chlorhexidine cannot be concluded with today’s knowledge. 
 
Acinetobacter spp. can be a part of the normal skin flora. Acinetobacter baumannii is an 
important nosocomial pathogen of increasing importance. Of special significance is the 
increasing frequency of resistance to a variety of antimicrobial agents. Unfortunately, little is 
known about the susceptibility of Acinetobacter spp. to disinfecting agents (Martro et al., 
2003; Wisplinghoff et al., 2007). 
 
We have not found any reports about reduced susceptibility to disinfectants among other 
microorganisms considered to be part of the normal flora of the skin.   
 
The microbiological flora of the skin can be exposed to chlorhexidine via various products 
like skin cleansing products, hand disinfectants, preoperative bathing formulations, and 
cosmetic products (Denton 1991; Milstone et al., 2008). Hand cleansing with chlorhexidine 
has been shown to reduce the number of microbes on skin by between 86 and 92 % (Askgaard 
1975; Lowbury & Lilly 1973). In general, skin cleansing with chlorhexidine significantly 
reduces normal skin flora, Gram-negative organisms, and S. aureus (Denton 1991). Whole 
body washing with chlorhexidine is reported to reduce skin colonisation (Brandberg 1989; 
Davies et al., 1997; Kaiser et al., 1988). Little knowledge is available on potential selection of 
certain types of bacteria after such exposure. In a study of bathing in a 4 % chlorhexidine 
solution, counts of S. aureus and Gram-negative bacteria  after treatment were no different to 
those from before treatment (Davies et al., 1997). In another study, it was found that whole 
body washing with 4 % chlorhexidine reduced MRSA at one sample site, but no effect was 
detected at other sample sites (Wendt et al., 2007). 
 
To our knowledge, no data exist on how cosmetics containing chlorhexidine will affect the 
skin flora, and the selection pressure on the normal flora of the skin from chlorhexidine in 
cosmetic products is not easily predicted.  
 
Oral microflora 
The oral cavity is colonized by a wide range of mircoorganisms in complex ecosystems that 
change throughout life. The oral microbiota is one of the most complex mixtures of bacteria 
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known. A recent report using pyrosequencing analyses estimated the number of species-level 
phylotypes to be greater than 19000 (Keijser et al., 2008), with 97 % of the sequences 
occurring in 45 genera. The most prevalent species belonged to the Streptococcus, 
Veillonella, Corynebacterium, Actinomyces, Fusobacterium, Prevotella, Neisseria, 
Porphyromonas, and Haemophilus genera.  Less than 50 % of the flora were cultivable. 
Commensal streptococci constitute a major part of the oral bacterial flora that gradually 
becomes more complex with time. Among the oral streptococci, Streptococcus mitis is the 
most prevalent (Aas et al., 2005). The streptococci form the basis for adhesion of other 
colonizing bacteria, such as Actinomyces and Veillonella species. The composition varies at 
various sites in the oral cavity, depending on nutrient availability, salivary flow rate, and 
oxygen tension, as well as on the host’s dental and gingival health conditions, diet, and age. 
The commensal oral bacteria exist mainly as biofilms on mucosal and tooth surfaces. The 
flora also protects against colonization by potential pathogenic bacteria like S. aureus, E. 
faecalis, Streptococcus pneumoniae, Streptococcus pyogenes, Neisseria species, members of 
the Enterobacteriaceae family, H. influenza, and actinomycetes  (Sweeney et al., 2004). 
Therefore, disruption of the ecological balance by antimicrobial agents may have an impact 
on the health of the individual (Avila et al., 2009).  
  
Mouthwashes containing chlorhexidine are mainly advertised as anti-halitosis agents. 
Chlorhexidine mouthwash has been studied also for its effect on oral biofilms and dental 
diseases, and even for prevention of ventilator-associated pneumonia (Hutchins et al., 2009). 
The use of chlorhexidine as a mouthrinse is related to its ability to adsorb onto a variety of 
surfaces and to its broad spectrum of antimicrobial activity over a wide pH range. Being 
cationic, the molecules can bind to carboxyl-, phosphate- and hydroxyl-groups of negatively 
charged surfaces. This allows the agent to bind to oral mucosal surfaces and to remain in the 
oral cavity for prolonged periods. This so-called substantivity is considered important for the 
oral antibiofilm effects, although chlorhexidine loses some of its activity upon adsorption to 
surfaces (Baker et al., 1978; Moran & Addy 1984) 
 
Numerous studies confirm the preventive effect of chlorhexidine mouthrinses on dental 
biofilm formation and gingivitis development. Chlorhexidine is regarded as the most 
efficacious agent in reducing accretion of biofilm on teeth, and chlorhexidine mouthrinse has 
been included in numerous studies as the “gold standard” against which the efficacy of other 
agents may be compared (Petersen & Scheie 1998). A single mouthrinse with 0.2 % 
chlorhexidine reduces  oral flora by between 80 and 95 % (Schiott 1973). The control of 
dental biofilms is central for oral health maintenance, and therefore chlorhexidine 
mouthrinsing represents a useful adjunct for subjects unable to perform effective conventional 
mechanical tooth cleaning.  
 
There has been little focus on the possibility of chlorhexidine resistance development or 
development of co- or cross-resistance with antibiotics among members of the oral flora. In 
an early study, it was concluded that two years of daily mouthrinses with chlorhexidine 
resulted in a slight change in distribution towards bacteria that were less sensitive to 
chlorhexidine (Schiott et al., 1976a). In 1980, chlorhexidine-sensitive S. sanguis ATCC10558 
(now Streptococcus gordonii) was shown to develop tolerance to chlorhexidine upon growth 
in continuous culture under exposure to chlorhexidine (see section 5.3.2) (Westergren & 
Emilson 1980).   
 
A total of 424 clinical S. mutans isolates were studied in Finland for chlorhexidine 
susceptibility, along with susceptibility to amoxicillin, penicillin, cefuroxime, erythromycin, 
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tetracycline and sulphamethoxazole-trimethoprim (Järvinen et al., 1993). Chlorhexidine was 
highly effective against all the S. mutans isolates and the MIC did not exceed 1 mg/L. The 
strains were also sensitive to the antibiotics tested. The authors concluded that although there 
is an increasing and continuous selection pressure on the oral microbiota from chlorhexidine 
mouthrinses, oral S. mutans has remained susceptible in Finland (Järvinen et al., 1993). The 
mouthrinsing habits of the test subjects were, however, unknown, and therefore their actual 
chlorhexidine exposure is uncertain.  
 
The effect of pulsing chlorhexidine on oral bacterial ecosystems, including ten oral bacteria, 
was studied in vitro. The results of this study (McBain et al., 2003) support the previous 
observation that chlorhexidine alters the susceptibility distribution (Schiott et al., 1976b), but 
concluded that there were no significant alterations in distribution of sensitivity to chemically 
unrelated biocides or antibiotics including triclosan, erythromycin, penicillinV, vancomycin, 
and metronidazole. Notably, the chlorhexidine exposure lasted for only five days. The 
bacteria studied were laboratory strains of Actinomyces naeslundii, Fusobacterium nucleatum, 
Lactobacillus rhamnosus, Neisseria subflava, Prevotella nigrescens, P. gingivalis, S. mutans, 
S. sanguis, S. oralis, and Veillonella dispar.  
 
Based on the few clinical studies on susceptibility change or resistance development in 
response to chlorhexidine exposure, Sreenivasan and Gaffar concluded in a review article that 
chlorhexidine reduces dental biofilm, but without altering the microbial tolerance to either 
chlorhexidine or to commonly used antibiotics (Sreenivasan & Gaffar 2002). 
 
The oral microflora, including the early tooth colonizers S. gordonii, S. oralis, and S. mitis 
constitute a pool of genetic material both from cells inhabiting the oral cavity, and from 
transiting cells (Hakenbeck et al., 1998; Seppala et al., 2003)). Several factors in the oral 
cavity, including competence factors for streptococci, could promote horizontal gene transfer 
among the bacteria. Furthermore, both naked DNA and bacteriophages can survive in human 
saliva. It has been shown experimentally that oral biofilms represent suitable environments 
for  genetic transfer to potential pathogens  (Roberts & Mullany 2006), and it is likely that this 
could also occur in vivo.  
 
The oral bacterium F. nucleatum co-aggregates with other oral species and plays a role in oral 
biofilm formation as a bridge between early and late colonizers (Kolenbrander & London 
1993). Exposing F. nucleatum to sub-inhibitory concentrations of chlorhexidine resulted in 
induced bacteriocine production (Okamota et al., 2000). Whether this might affect the oral 
ecology is, however, unknown. 
 
Environment 
As chlorhexidine compounds enter the environment via the sewage system they will 
inevitably act on environmental microbes. In a study by Lawrence et al. ( 2008), the effects of 
chlorhexidine on microbial biofilms from river water were examined. The authors observed 
significant effects of chlorhexidine at a concentration of 100 µg/L on the protozoan, algal, 
cyanobacterial, and bacterial biomass. At this concentration, a virtual elimination of the 
protozoan community in the biofilms could be observed, resulting in lowered grazing activity. 
 
Nuñez  and Moretton ( 2007) examined the bacterial resistance patterns to several 
disinfectants, including chlorhexidine, in hospital sewage effluents in Buenos Aires. Between 
103 and 106 chlorhexidine resistant bacteria/100 mL were isolated from the samples. The 
bacterial populations resistant to disinfectants were mainly members of the 
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Enterobacteriaceae family, Staphylococcus spp., and Bacillus spp. Bacterial isolates were 
tested for their resistance patterns by an agar dilution method using chlorhexidine in 
increasing concentrations. The chlorhexidine MIC in the resistant bacteria isolated from the 
hospital sewage ranged from 50 to 150 mg/L, and included Shigella dysenteriae, Shigella 
flexneri, P. vulgaris, Aeromonas hydrophila, Alcaligenes sp., Acinetobacter sp., and P. 
aeruginosa. The authors conclude that hospital effluents are of importance in the bacterial 
resistance selection process, particularly in the case of disinfectants. 
 
5.5 Resistance link between chlorhexidine compounds and other 
antimicrobial agents 
There are conflicting reports on whether there is a correlation between chlorhexidine 
tolerance and antibiotic resistance. Koljalg ( 2002)  reported good correlation between 
chlorhexidine and antibiotic susceptibility in both MIC and MBC among clinical Gram-
positive bacteria, and mainly in MBC among clinical Gram-negative bacteria. Resistance to 
ciprofloxaxin, imipenem, cefotaxime, ceftazidime, gentamicin, and aztreonam appeared to 
indicate increased chlorhexidine tolerance among Gram-negative bacteria  (Koljalg et al., 
2002). On the other hand, no link between vancomycin resistance and chlorhexidine tolerance 
in enterococci has been demonstrated, as vancomycin-resistant enterococci and vancomycin-
susceptible enterococci had equivalent susceptibility to chlorhexidine (Anderson et al., 1997). 
Studies on E. coli, P. aeruginosa, S. marcescens, and Proteus mirabilis have not revealed any 
increase in chlorhexidine resistance among antibiotic resistant bacteria (Michelbriand et al., 
1986; Sykes & Matthew 1976). Some reports indicate a higher MIC to chlorhexidine among 
MRSA compared with methicillin sensitive S. aureus (MSSA) (Brumfitt et al., 1985; 
Cookson et al., 1991; Mycock 1985). However, bactericidal activity is reported to be similar 
for MRSA and MSSA (Cookson et al., 1989; Haley et al., 1985).  Cookson ( 2005) discusses 
the relevance of increased chlorhexidine resistance (QacA mediated) among MRSA. The 
qacA-positive strains were not killed more slowly in an in vitro rate of kill test (Cookson et 
al., 1991). MSSA transcipients with the qacA gene transferred to them from MRSA were also 
killed rapidly in vitro and in vivo. Chlorhexidine MICs of MRSA isolates with different 
pulsed field gel electrophoresis genotypes from six geographically disparate hospitals were 
not further elevated 6 years after the first appearance of the strain. Additional unpublished 
data would suggest that the qacA chlorhexidine resistance gene did not convey a significant 
advantage to MRSA, in that resistance to gentamicin and chlorhexidine of the isolates referred 
to the reference laboratory, fell from approximately 90 % in 1984 to approximately 50 % in 
the late 1980s (Cookson 2005). 
 
Some efflux pumps have been shown to mediate export of both chlorhexidine compounds and 
other antimicrobial agents by the same pump. The available MIC levels of antimicrobial 
agents due to these pumps are only listed below if a clinical breakpoint is available for 
comparison. Clinical breakpoints given are according to the European committee on 
Antimicrobial Susceptibility testing (EUCAST) (http://www.eucast.org/clinical_breakpoints/) 
that are only available for those antimicrobial agents which are in clinical use in Europe 
against the bacteria in question. Among such chromosomally encoded efflux pumps are;  
• MepA in S. aureus transporting a range of structurally different compounds such as 
chlorhexidine, benzalkonium chloride, pentamidine, fluoroquinolones (MIC levels of 
0.16-1.25 mg/L, clinical breakpoint of >1 mg/L for the ciprofloxacin in 
staphylococci), and tigecycline (MIC levels of 4-16 mg/L, clinical breakpoint of >0.5 
mg/L) (Huet et al., 2008; Kaatz et al., 2005; McAleese et al., 2005).  
• E. coli AcrAB-TolC pump exporting biocides such as chlorhexidine, quaternary 
ammonium compounds and triclosan as well as penicillins (MIC levels of 2-32 mg/L, 
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clinical breakpoints of >8 mg/L in Enterobacteriaceae), cephalosporins, 
chloramphenicol (MIC level of 3.13 to >160 mg/L, clinical breakpoints of >8 mg/L), 
fusidic acid, macrolides, fluoroquinolones (MIC level of 3.13-20 mg/L, clinical 
breakpoints of >16 mg/L fro nalidixic acid), novobiocin, trimethoprim, tetracyclines 
(MIC level of 0.5 mg/L, clinical breakpoints of >2 mg/L), and rifampicin (Hirata et 
al., 2004; Levy 2002; Ma et al., 1993; McMurry et al., 1998; Nishino & Yamaguchi 
2001; Okusu et al., 1996).  
• Pump SdeXY in S. marcescens conferring reduced susceptibility to several 
antimicrobial agents including ampicillin (MIC level of 16 mg/L, clinical breakpoints 
of >8 mg/L in Enterobacteriaceae), erythromycin, tetracycline (MIC level of 16 mg/L, 
clinical breakpoints of >2 mg/L for tigecylcine), and ciprofloxacin (MIC level of >8 
mg/L, clinical breakpoints of >1 mg/L) in addition to benzalkonium chloride, triclosan 
and to a lesser extent chlorhexidine (Chen et al., 2003; Hornsey et al., 2010).  
• SdeAB in S. marcescens resulted in increased tolerance to chlorhexidine as well as to 
cetylpyridinium chloride, benzalkonium chloride, quinolones (MIC levels of 1.56-25 
mg/L, clinical breakpoints of >1 mg/L for norfloxacin and ofloxacin in 
Enterobacteriaceae), tetracycline, and chloramphenicol  (MIC level of 100 mg/L, 
clinical breakpoints of >8 mg/L) (Maseda H et al., 2009).  
• The MexCD-OprJ pump in P. aeruginosa induced by chlorhexidine to enhance 
tolerance to chlorhexidine and also to clinically relevant antibiotics such as quinolones  
(MIC levels of 2->4096 mg/L, clinical breakpoints of >1 mg/L for ciprofloxacin and 
>2 mg/L for levofloxacin in Pseudomonas), macrolides, tetracyclines, lincomycin, 
chloramphenicol, novobiocin, some penicillins  (MIC level of 1-4096 mg/L, clinical 
breakpoints of >16 mg/L), and some cephems  (MIC levels of 0.5-256 mg/L, clinical 
breakpoints of >8 mg/L for cefepime and ceftazidime) (Fraud et al., 2008; Masuda et 
al., 2000; Morita et al., 2003). 
 
QacA plasmid-encoded efflux pumps are common in clinical strains of S. aureus and other 
staphylococci specifying tolerance to structurally dissimilar cations such as chlorhexidine, 
benzalkonium chloride, and cetrimide (Littlejohn et al., 1992; Paulsen et al., 1996; Poole 
2002). The qacA gene is typically found on multi-resistance plasmids that may encode 
resistance to aminoglycosides, penicillin, tetracycline, and trimethoprim (Archer et al., 1986; 
Leelaporn et al., 1994; Paulsen et al., 1996; Sidhu et al., 2002; Tennent et al., 1989). A 
gentamicin resistance plasmid carrying qacA was found in an MRSA clone in the United 
Kingdom (Cookson 2005). qacA/B and a gene conferring resistance to β-lactams have proved 
to co-reside on large plasmids in various staphylococcal species of both clinical and food-
processing origin (Anthonisen et al., 2002; Bjorland et al., 2005; Sidhu et al., 2002; Sidhu et 
al., 2001) and such plasmids can be taken up by plasmid-free S. aureus, indicating that the 
resistance genes have the potential to be transferred to pathogens under selective stress (Sidhu 
et al., 2001).  
 
An unnamed antiseptic resistance protein, differing from QacA in size and providing 
tolerance to chlorhexidine and benzalkonium chloride, was found encoded on a transferable 
50-kb plasmid in MRSA also harbouring resistance to aminoglycosides (Yamamoto et al., 
1988). 
 
Cell wall changes may also play a role as common resistance mechanism between 
chlorhexidine compounds and other antimicrobial agents by reducing permeability. P. stutzeri 
that developed stable resistance to chlorhexidine also demonstrated a variable increase in 
resistance to polymyxin B, gentamicin, nalidixic acid, erythromycin, and ampicillin 
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(Tattawasart et al., 1999). Salmonella enterica serovar Virchow that had adapted to 
chlorhexidine demonstrated cross-resistance to tetracycline and triclosan, whereas E. coli 
O157 demonstrated cross-resistance to triclosan (Braoudaki & Hilton 2004). 
 
In summary, it is mainly intrinsic mechanisms that show cross-resistance and few acquired 
mechanisms show co-resistance to chlorhexidine and other antimicrobial agents, including 
clinically relevant antibiotics among some human pathogens, e.g. S. aureus. The resulting 
tolerance levels from both intrinsic mechanisms (5.3.1) and from the presence of the acquired 
resistance mechanisms, including acquisition of the qacA gene (5.3.2), are far less than the 
commonly used chlorhexidine concentrations of up to 3 g/L in cosmetic products. On the 
other hand, it may be speculated that exposure of bacteria to residual concentrations of 
chlorhexidine from cosmetics might favour the spread of resistance towards clinically 
important antimicrobials. Evidence for a role of chlorhexidine-containing cosmetics in such 
resistance development is, however, lacking. 
 
6 Link between resistance to chlorhexidine compounds and 
pathogenicity; genotype and phenotype 
 
The link between resistance to chlorhexidine and pathogenicity has been little studied. Some 
studies indicate that exposure to low doses of chlorhexidine may render microorganisms less 
virulent. Galice et al. ( 2006) showed that growth of Streptococcus agalactiae in the presence 
of sub-inhibitory concentrations of chlorhexidine resulted in lower toxin production, but the 
mechanism behind this was not determined. Similarly, exposure of C. albicans to 
chlorhexidine resulted in reduced phospholipase activity, an important pathogenicity factor 
(Kadir et al., 2007). 
 
Efflux pumps that confer antimicrobial resistance in microorganisms probably have greater 
clinical relevance than previously assumed. Certain classes of efflux pumps not only harbour 
resistance to antimicrobial agents used in therapy, but also have a role in bacterial 
pathogenicity. Efflux pumps that export antimicrobial agents may also export virulence 
determinants, such as adhesins, toxins, and other proteins that are important for colonization 
and survival of bacteria in their hosts (Piddock 2006). Piddock ( 2006) reviewed several 
studies that demonstrate that the lack of efflux pump expression by Gram-negative bacteria 
(like S. enterica serovar Typhimurium, E. coli, Erwinia amylovora, P. aeruginosa, 
Campylobacter jejuni, and Neisseria gonorrhoeae) has a deleterious effect on the ability of 
the bacteria to be pathogenic in animal models. Recently, it was reported that lack of AcrAB 
in K. pneumoniae not only resulted in higher susceptibility to several antibiotics, but also to 
reduced capacity to cause pneumonia in a mouse model. There is, however, a lack of studies 
on the pathogenicity of mutants over-expressing efflux pumps associated with reduced 
susceptibility to chlorhexidine. 
 
Most mutations or acquired elements that provide resistance also introduce some biological 
cost to their host, although genetic adaptations are likely to reduce this fitness burden 
(Andersson & Levin 1999). Studies on the fitness cost of expressing chlorhexidine resistance 
genes have not been published, but through their role as exporters of multiple substances it is 
possible that some of these efflux pumps may express chlorhexidine resistance accompanied 
by a fitness benefit. Derepression of a multidrug efflux pump, MtrC-MtrD-MtrE in N. 
gonorrhoeae, belonging to the same efflux pump family as the AcrAB-TolC that contributes 
to chlorhexidine resistance in E. coli, increased both resistance to multiple antibiotics and, at 
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the same time, provided a fitness benefit in vivo. This resulted in increased gonococcal 
survival and infectivity, probably through export of natural immune effectors at the infection 
site (Warner et al., 2007).  
Biofilm formation is considered an important virulence factor for S. epidermidis and 
chlorhexidine is used to prevent biofilm formation in medical applications. A small increase 
in biofilm formation of S. epidermidis on polystyrene when exposed to sub-inhibitory 
concentrations of chlorhexidine in a laboratory model has been observed (Houari & Di 
Martino P. 2007). Concentrations of 0.00 2% or higher prevented biofilm formation.  No 
induction of biofilm growth was found for other bacteria tested (E. coli, K. pneumoniae, P. 
aeruginosa). As far as we know, increased biofilm formation of staphylococci during 
application of chlorhexidine has not been reported.  
7 Exposure assessment 
Chlorhexidine and its salts may be added to cosmetics, as active ingredients or as 
preservatives, at concentrations of up to 0.3 %, according to current EU legislation (Council 
Directive 76/768/EEC). In the EU countries reliable information on products containing 
chlorhexidine is almost absent. According to the Voluntary Cosmetic Registration Program 
(VCRP) provided by Food and Drug Administration in USA 
(http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/VoluntaryCosm
eticsRegistrationProgramVCRP/default.htm),  chlorhexidine and its salts are used as active 
ingredients in 43 cosmetic products, and as preservatives in 95 cosmetic products. 
Furthermore, The Environmental Working Group database in USA (www.ewg.org) reports 
that chlorhexidine or its salts are included in 979 cosmetic products on the American market.  
These products include hair dying and bleaching formulations, shampoos, anti hair “aging” 
products and exfoliants, body lotions, eye creams, face cleansers, sun cream, after-sun lotions, 
eye makeup removers, facial masks, and mouthrinses. Approximately 80 % of the cosmetic 
products containing chlorhexidine in this database are intended for hair treatments, and 
therefore not intended for prolonged contact with the body. The Environmental Working 
Group database reports that, in cosmetic products, chlorhexidine is commonly combined with 
other agents possessing antimicrobial activity, such as parabens, phenoxyethanol, 
chlorphenesin, triclosan, hydantoin, benzalkonium chloride, hydroxypropyl trimonium 
chloride, sorbate, iodine propynyl butylcarbamate, and benetrimonium methosulphate. The 
combined effect of these agents on microorganisms is not easily assessed. 
 
Creams and lotions containing chlorhexidinemay leave residual concentrations that are below 
MIC for some bacteria. As for mouthrinses, it has been estimated that by rinsing with 10 ml 
of a 0.2 % chlorhexidine solution, 67 % will be spat out, 3 % will be swallowed, while 30 % 
will be bound to mucosal surfaces and subsequently slowly released over a period of time 
(Gjermo et al., 1975). It is generally accepted that the retention and subsequent slow release 
of the agent is crucial for the effect on dental biofilms and prevention of gingivitis 
development. Upon dermal application of 5 ml of 5 % chlorhexidine solution, it was found 
that more than 60 % of the chlorhexidine present 5 minutes after application remained even 
after 6 h, while 17 % remained after 24 h (Carret et al., 1997). The binding and slow release 







In cosmetic products, chlorhexidine is added to mouthwashes with the intention of halitosis 
reduction and to prevent dental biofilm formation and gingivitis development. As an example, 
chlorhexidine is reported to be used in the following product types in Norway: Corsodyl 
Mouthwash, Denivit Original Denivit Mint, Solidox Frisk Pust Munnskyllevann (NFSA).  
 
The available information on chlorhexidine use is limited, thus the figures given here are only 
coarse estimates. The total use of chlorhexidine included in cosmetic products has been 
estimated by NFSA to be 200 kg. This includes chlorhexidine included in mouthrinse 
products and hair products. Chlorhexidine found in cosmetics purchased by Norwegians 
during travel abroad is not included.  
 
In addition to cosmetic products, chlorhexidine is also found in medical formulations. Such 
formulations may be used for preoperative skin disinfection, in treatment of wounds and 
burns, for urinary bladder flushing and in catheter disinfection, in ophthalmology and 
gynaecology. In Norway eight medical products are currently registered. These products 
contain chlorhexidine in concentrations from 0.05 to 4 %.  The yearly consumption of 
chlorhexidine in these products is estimated to be 2 254 kg (www.whocc.no). 
 
8 Data gaps 
There seems to be a lack of reliable data on the use of chlorhexidine in cosmetic products, the 
food industry, in dental practices, as well as for veterinary and human medical purposes. 
Therefore the relative importance of cosmetic products containing chlorhexidine for 
development of resistance is difficult to quantify. 
 
Published information on the pharmacokinetics of chlorhexidine compounds is scarce. The 
stability of these agents on the skin and mucous membranes is not well described, and the 
absorption, distribution, metabolism, and excretion in animals and humans are not thoroughly 
described in the available literature. 
 
Few studies have been conducted that test chlorhexidine susceptibility under conditions of 
practical use. Moreover, there are few studies investigating acquired chlorhexidine resistance 
in bacteria. Most studies exploring the substrate specificities of novel resistance 
mechanisms/genes, test resistance to quaternary ammonium compounds rather than 
chlorhexidine should a biocide be included in the test panel.  
 
Conclusive information on the development of resistance due to chlorhexidine in general, and 
in cosmetic products in particular, is currently lacking. The available literature on resistance 
towards chlorhexidine and co- and cross-resistance to other antimicrobial agents is generally 
old. The situation may have changed with respect to resistance patterns, and the available 
literature may not reflect the current situation.  
 
Knowledge about changes in the virulence of microbes of the oral cavity or skin microbiota 
due to chlorhexidine exposure is scarce. 
 
We have not been able to find any studies that reveal how much QacA contributes to the 




9 Risk characterization:  Answers to the questions 
9.1 Could the use of chlorhexidine in cosmetic products facilitate the development of 
resistance or reduced susceptibility towards chlorhexidine in microorganisms? 
Chlorhexidine has been used for over 50 years, primarily in clinical applications. As far as we 
know, treatment failure due to acquired resistance has not been reported. Acquisition of 
resistance in laboratory tests has been reported, but the tolerance levels are relatively low. 
However, it is not clear whether tolerant mutants could survive in practical applications as the 
test methods for resistance are often based on growth inhibition, and low correlation with the 
bactericidal effect has been reported. Little is known about the mechanisms behind acquired 
resistance to chlorhexidine. The most studied mechanism is the multidrug efflux pump, QacA, 
which also confers reduced susceptibility to several related antimicrobials. This plasmid-
borne determinant is widespread among clinical S. aureus strains. The prevalence of S. aureus 
harbouring QacA in domestic products, including cosmetics, is not known. It has never been 
proven that QacA confers resistance to either medical or cosmetic user-concentrations of 
chlorhexidine. 
 
The use of chlorhexidine is more limited in cosmetics than in clinical products, and resistance 
has been less extensively investigated. Based on present knowledge, development of 
resistance due to the use of chlorhexidine in cosmetics cannot be excluded. However, 
resistance development is probably less common for chlorhexidine than for antibiotics or 
biocides containing quaternary ammonium compounds. 
 
9.2 Could the efficacy of clinically important antimicrobials be reduced by resistance 
development due to application of chlorhexidine in cosmetic products? If so, which 
classes of agents might be affected? 
Some reports have shown that there are resistance links between chlorhexidine and other 
antimicrobial agents (see section 5.5).  
 
Cross-resistance can be mediated by efflux pumps in both Gram-negative and Gram-positive 
bacteria that have been shown to export both chlorhexidine and clinically important 
antimicrobial agents. Such plasmid-encoded efflux pumps (QacA), which so far only have 
been reported in staphylococci, may confer resistance to other biocides such as quaternary 
ammonium compounds. Chromosomally encoded efflux pumps may also transport clinically 
important antibacterial agents in classes including macrolides, β-lactams, quinolones, 
amphenicols, trimethoprim, rifamycin, fusidic acid, tetracyclines, and lincomycin, the anti-
protozoan pentamidin, or biocides such as quaternary ammonium compounds and triclosan. 
Chromosomally encoded pumps must often be induced to confer resistance and, even after 
over-expression, the levels of antibiotic resistance are sometimes relatively low and unlikely 
to compromise therapeutic effectiveness. However, some human pathogens show MIC levels 
above clinical breakpoints for; i) a novel tetracycline (S. aureus), ii) β-lactams, quinolones, 
amphenicols, and tetracyclines (Enterobacteriacea), and iii) β-lactams and quinolones (P. 
aeruginosa).  
 
Plasmids showing co-resistance to chlorhexidine and to clinically important antibacterial 
agent classes such as aminoglycosides, β-lactams, tetracyclines, and trimethoprim have been 
shown to disseminate between staphylococci. Co-localisation of resistance determinants to 
chlorhexidine and other antibacterial agents, on mobile elements such as plasmids, may also 
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contribute to transfer of resistance to other bacteria and be selected for in an environment 
where the chlorhexidine levels are below the MIC levels. 
 
In summary, there is some evidence of co- and cross-resistance between chlorhexidine and a 
range of unrelated antibacterial agents such as antibiotics and disinfectants. The tolerance 
level of microorganisms to chlorhexidine is generally low and probably not of clinical 
importance. However, application of chlorhexidine in cosmetic products may lead to exposure 
to highly variable concentrations. Exposure to sub-inhibitory concentrations may contribute to 
increased occurrence of resistance to clinically important antimicrobial agents. However the 
contribution of chlorhexidine in cosmetic products to such resistance compared with their use 
in other applications or the use of antibacterial agents in clinical practice is probably of lesser 
significance.  
 
9.3 Could use of chlorhexidine in cosmetic products alter the microflora of the skin or 
the oral cavity, or influence the virulence of these microorganisms? 
To our knowledge, there are only a few clinical studies on the effect of chlorhexidine on skin 
microbiota and no studies on the use of cosmetics. For oral microbiota there are only a few 
studies on the effect of chlorhexidine in mouthrinses. Since Gram-negative bacteria are 
generally more tolerant to chlorhexidine than Gram-positive bacteria, one could expect there 
to be selection of Gram-negative flora on skin, but studies do not indicate that such selection 
occurs. There is a clear need for investigations on the effects after long-term use. The 
association between tolerance to chlorhexidine and virulence has been little studied, but two 
publications report a reduction in virulence after exposure to chlorhexidine. The intrinsic 
resistance mechanisms found in bacteria are also involved in virulence, but increased 
expression of these mechanisms and the potential effect on virulence has not been 
investigated. It would be speculative to conclude that chlorhexidine leads to induction of 
intrinsic mechanisms involved in virulence or increased fitness. In conclusion, there are 
presently no indications that the use of chlorhexidine alters the microflora of the skin or the 





Chlorhexidine is used in a wide range of products, including cosmetic products.  
 
Although some information is available, there seems to be a lack of reliable data on the 
amounts of chlorhexidine used. 
 
The main conclusions on the questions raised by The Norwegian Food Safety Authority in the 
Terms of reference are: 
 
• Conclusive information on the development of resistance due to chlorhexidine in 
cosmetic products is currently lacking. 
• Although the literature is not conclusive, it is probable that chlorhexidine in 
cosmetic products adds to the selection pressure towards more chlorhexidine-
tolerant microorganisms among the skin and mouth flora. 
• Intrinsic or acquired low level resistance/tolerance towards chlorhexidine is found in 
a diverse range of microorganisms, and this tolerance is facilitated by several 
mechanisms. However, the resistance levels are far less than that of the commonly 
used chlorhexidine concentrations of up to 3 g/L in cosmetic products. 
• There are conflicting reports on the correlation between chlorhexidine and antibiotic 
resistance. However, some efflux pumps have been shown to mediate export of both 
chlorhexidine (although at a level far below the commonly used chlorhexidine 
concentrations in cosmetic products) and clinically important antimicrobial agents 
(β-lactams, quinolones, amphenicols and tetracyclines) at levels above the clinical 
MIC breakpoints. Furthermore, cell wall changes that reduce the permeability may 
also play a role as a common resistance mechanism between chlorhexidine and other 
antimicrobial agents, some of which are of clinical importance. Furthermore, 
dissemination of multi-resistant plasmids between staphylococci showing co-
resistance to chlorhexidine and clinically important antibacterial agent classes such 
as aminoglycosides, β-lactams, tetracyclines, and trimethoprim has been reported. 
Although chlorhexidine tolerance levels are far lower than the commonly used 
concentrations in cosmetic products, the contribution to increased occurrence of 
resistance to clinically important antimicrobial agents by chlorhexidine in cosmetic 
products cannot be excluded. However, data exploring the range of chlorhexidine 
concentrations upon cosmetic use and their influence upon selection of co- or cross-
resistance towards clinically important antibiotics are currently lacking. 
• At present there are no indications that the use of chlorhexidine alters the microflora 
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